Jubiglim M 1 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 1mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glycemic control. The synergistic action of these two agents addresses multiple pathophysiological defects in type 2 diabetes, making Jubiglim M 1 Tablet PR effective in achieving and maintaining target blood glucose levels. It is recommended as an adjunct to diet and exercise in patients inadequately controlled on either monotherapy or lifestyle modifications alone. The medication should be administered with meals to minimize gastrointestinal side effects commonly associated with Metformin. Caution is advised in patients with renal or hepatic impairment, and regular monitoring of blood glucose, renal function, and hepatic enzymes is essential during therapy. Potential adverse effects include hypoglycemia, gastrointestinal disturbances, and rare lactic acidosis. Jubiglim M 1 Tablet PR should be prescribed under medical supervision, with individualized dosing based on patient response and tolerability to optimize therapeutic outcomes.